Insights

Professional
Practice
Industry
Region
Trending Topics
Location
Type

Sort by:

Firm News 43 results

Firm News | 3 min read | 04.01.24

Crowell Earns Top Rankings in Legal 500 EMEA 2024

Brussels and Doha – April 1, 2024: The Legal 500 Europe, Middle East & Africa (EMEA) 2024 edition has recognized 16 practice areas and 11 lawyers in Crowell & Moring’s Brussels and Doha offices. The 11 individual lawyers received 18 total rankings across the 16 different practice areas.
...

Firm News | 2 min read | 03.14.24

Chambers Ranks Crowell Lawyers and Practices in 2024 Europe Guide

Chambers and Partners has ranked five Crowell & Moring practice groups and seven individual lawyers in the Chambers Europe 2024 guide.

Firm News | 2 min read | 03.20.23

Chambers Ranks Six Crowell Lawyers and Four Practice Groups in 2023 Europe Guide

Brussels – March 20, 2023: Chambers and Partners has ranked four Crowell & Moring practice groups and six individual lawyers in the Chambers Europe 2023 guide. The rankings are driven by independent interviews of clients and members of the legal community.
...

Client Alerts 73 results

Client Alert | 4 min read | 03.27.25

Proposed Bills Limit Pharmaceutical Patents: Panacea for Patients or Poison for Pharmaceutical Producers?

Senators John Cornyn(R-Texas), Chuck Grassley (R-Iowa), Richard Blumenthal (D-Conn.), and Dick Durbin (D.-Ill.) recently sponsored two bills, introduced on March 14th, that would affect patents in the pharmaceutical industry.
...

Client Alert | 4 min read | 03.25.25

Federal Circuit Affirms Deductibility of Hatch-Waxman Litigation Expenses

In a significant decision for generic drug manufacturers, the Federal Circuit recently affirmed that litigation expenses incurred in defending Hatch-Waxman patent lawsuits are deductible as ordinary and necessary business expenses under the Internal Revenue Code (IRC). The ruling in Actavis Laboratories FL, Inc. v. United States, No. 23-1320 (Fed. Cir. Mar. 21, 2025), resolves a key tax dispute, allowing tax deductions for these expenses in the year they are incurred rather than capitalizing them over time. This outcome provides clarity and potential tax benefits for qualifying businesses navigating the interplay of patent litigation and FDA drug approvals.
...

Client Alert | 4 min read | 03.24.25

USPTO Finds Claims of Two of Moderna’s mRNA Patents Unpatentable: What’s Next in the Vaccine Wars?

On Wednesday, March 5, 2025, the United States Patent Trial and Appeal Board (“PTAB”) handed down the latest decision in the COVID vaccine proceedings between Pfizer Inc. (“Pfizer”) and BioNTech SE (“BioNTech”) and ModernaTX, Inc. (“Moderna”). The PTAB found all challenged claims unpatentable in two patents held by Moderna related to Moderna’s COVID-19 vaccine technology: U.S. Patent Nos. 10,702,600 (the “’600 patent”) and 10,933,127 (the “’127 patent”), both entitled “Betacoronavirus mRNA Vaccine.”
...

Press Coverage 8 results

Publications 23 results

Publication | 01.15.25

Product Liability: Class Actions Are Increasingly Using Economic Loss To Bring Claims

A trend in product liability litigation has emerged over the past few years: Plaintiffs’ attorneys are increasingly choosing to bring class actions based on “economic loss” instead of the more traditional personal injury claim.
...

Events 4 results

Event | 02.25.25, 5:00 PM EST - 8:00 PM EST

Charting a Path for Compliance in Life Sciences

Join us for an interactive and educational event tailored for biotech leaders seeking to ensure security compliance while leveraging the power of Amazon Web Services (AWS). This session will dive into the critical elements of designing secure, scalable, and compliant systems for biotech operations, from research and development to clinical trials and beyond.
...

Event | 12.03.24, 8:30 AM EST - 9:30 AM EST

29th Annual Drug & Medical Device Litigation Conference

2024 has been a pivotal year for drug and medical device litigation, marked by significant case law developments that have reshape the landscape.

Event | 10.24.24, 5:30 PM EDT - 7:30 PM EDT

Do We Need a New Approach for Investing and Raising Funds in This Election Cycle?: A Fireside Chat and Networking Event for Emerging Companies and Investors

Join us for a networking event co-hosted by NYBIO and Crowell & Moring on October 24 between 5:30 and 7:30 pm. We will kick off the evening with a fireside chat moderated by Linda Malek, partner in the Healthcare and Privacy/Cybersecurity practices at Crowell in discussion with Andrew Lam, Managing Director and Head of Biotech Private Equity, Ally Bridge Group and Prem Premsrirut, Founder and CEO, Mirimus Inc. and Executive Director of Micoy Therapeutics.

Speaking Engagements 28 results

Blog Posts 3 results

Blog Post | 10.29.21

FDA Publishes Principles for AI and ML in Medical Devices

Crowell & Moring's Health Law Blog

Blog Post | 07.27.16

Beauty with a Side of Mercury?

Crowell & Moring's Retail & Consumer Products Law Observer